Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07818265) titled 'Differentiating True Nephrotoxicity From Pseudo-nephrotoxicity: A Prospective Comparative Study of Vancomycin Plus Piperacillin-Tazobactam vs. Meropenem Using Serum Creatinine and Cystatin-C' on Sept. 7.
Study Type: Observational
Primary Sponsor: King Faisal Specialist Hospital & Research Center
Condition:
Nephrotoxicity
Bacterial Infections
Acute Kidney Injury
Renal Impairment
Recruitment Status: Not recruiting
Date of First Enrollment: September 15, 2026
Target Sample Size: 304
Countries of Recruitment:
Saudi Arabia
To know more, visit https://clinicaltrials.gov/study/NCT07818265
Published by HT Digital...